TWI596115B - 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體 - Google Patents

具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體 Download PDF

Info

Publication number
TWI596115B
TWI596115B TW102128784A TW102128784A TWI596115B TW I596115 B TWI596115 B TW I596115B TW 102128784 A TW102128784 A TW 102128784A TW 102128784 A TW102128784 A TW 102128784A TW I596115 B TWI596115 B TW I596115B
Authority
TW
Taiwan
Prior art keywords
antibody
pcsk9
synthetic
artificial sequence
antigen
Prior art date
Application number
TW102128784A
Other languages
English (en)
Chinese (zh)
Other versions
TW201420605A (zh
Inventor
喬治 洋寇普羅斯
尼可拉斯 帕帕度普羅斯
安德魯 墨菲
尼爾 史塔賀
Original Assignee
再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 再生元醫藥公司 filed Critical 再生元醫藥公司
Publication of TW201420605A publication Critical patent/TW201420605A/zh
Application granted granted Critical
Publication of TWI596115B publication Critical patent/TWI596115B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW102128784A 2012-08-13 2013-08-12 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體 TWI596115B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682349P 2012-08-13 2012-08-13
US201261703342P 2012-09-20 2012-09-20
US201261734398P 2012-12-07 2012-12-07
US201361761383P 2013-02-06 2013-02-06
US201361828258P 2013-05-29 2013-05-29

Publications (2)

Publication Number Publication Date
TW201420605A TW201420605A (zh) 2014-06-01
TWI596115B true TWI596115B (zh) 2017-08-21

Family

ID=50066319

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102128784A TWI596115B (zh) 2012-08-13 2013-08-12 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體

Country Status (15)

Country Link
US (1) US9540449B2 (enExample)
EP (1) EP2882778B1 (enExample)
JP (1) JP6309521B2 (enExample)
KR (1) KR20150041662A (enExample)
CN (1) CN104540852B (enExample)
AR (1) AR092098A1 (enExample)
AU (1) AU2013302925B2 (enExample)
CA (1) CA2881679C (enExample)
EA (1) EA028244B1 (enExample)
IL (1) IL236785B (enExample)
MX (1) MX363213B (enExample)
NZ (1) NZ704771A (enExample)
TW (1) TWI596115B (enExample)
UY (1) UY34975A (enExample)
WO (1) WO2014028354A1 (enExample)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
EP3318633A1 (en) 2010-11-17 2018-05-09 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012101253A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HRP20241450T1 (hr) 2011-09-16 2025-01-03 Regeneron Pharmaceuticals, Inc. Postupci za smanjivanje razina lipoproteina(a) putem primjene inhibitora proproteinske konvertaze suptilizin keksin 9 (pcsk9)
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA2857159C (en) 2011-11-30 2024-05-07 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
EP2889377B1 (en) 2012-08-24 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Fcyriib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014104165A1 (ja) 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
ES2657304T3 (es) * 2013-03-15 2018-03-02 Bayer Healthcare Llc Variantes de anticuerpo anti TFPI con unión diferencial a lo largo del intervalo de pH para mejorar la farmacocinética
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EP2982689B1 (en) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
WO2014197752A1 (en) 2013-06-07 2014-12-11 Regeneron Pharmaceuticals, Inc. Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
EP3169353B1 (en) 2014-07-16 2019-12-18 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
RS62749B1 (sr) 2014-12-19 2022-01-31 Chugai Pharmaceutical Co Ltd Anti-c5 antitela i načini njihove upotrebe
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
EP4089113B1 (en) 2015-03-31 2023-12-13 Sorriso Pharmaceuticals, Inc. Polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
KR20170132749A (ko) * 2015-03-31 2017-12-04 브이에이치스퀘어드 리미티드 폴리펩티드
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN115925961A (zh) * 2015-05-28 2023-04-07 生物辐射实验室股份有限公司 亲和配体及其相关方法
CN106084058B (zh) * 2015-07-15 2019-08-27 北京天广实生物技术股份有限公司 抗人pcsk9单克隆抗体
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
JP6142069B1 (ja) * 2015-12-18 2017-06-07 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
SG10201709415WA (en) * 2015-12-18 2017-12-28 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION
JP2019509714A (ja) * 2016-01-05 2019-04-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
TW201735947A (zh) 2016-03-14 2017-10-16 Chugai Pharmaceutical Co Ltd 用於癌之治療的細胞傷害誘導治療劑
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN105801701B (zh) * 2016-03-31 2019-03-29 河北仁博科技有限公司 一种pcsk9抗体的重链和轻链可变区及其应用
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
TWI789369B (zh) * 2016-06-17 2023-01-11 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
JP7222901B2 (ja) 2017-03-16 2023-02-15 メドイミューン・リミテッド 抗ｐａｒ２抗体及びその使用
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
WO2019010191A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN
IL274265B1 (en) 2017-11-01 2025-09-01 Chugai Pharmaceutical Co Ltd Variant and isoform of an antibody with attenuated biological activity
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
JP7321159B2 (ja) 2017-12-22 2023-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 薬剤生成物不純物を特性決定するためのシステム及び方法
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
EP3759242A1 (en) 2018-02-28 2021-01-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TWI854343B (zh) 2018-03-19 2024-09-01 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
WO2020032230A1 (ja) 2018-08-10 2020-02-13 中外製薬株式会社 抗ｃｄ１３７抗原結合分子およびその使用
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
CA3100038A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
IL321750A (en) * 2018-10-31 2025-08-01 Bioatla Llc Anti-ctla4 antibodies, antibody fragments, immunoconjugates thereof and their uses
EA202191841A1 (ru) 2019-01-16 2021-10-07 Ридженерон Фармасьютикалз, Инк. Способы для идентификации свободных тиолов в белках
CN119119023A (zh) 2019-01-18 2024-12-13 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
US12478674B2 (en) 2019-04-18 2025-11-25 Bristol-Myers Squibb Company Ipilimumab variants with enhanced specificity for binding at low pH
MX2021013519A (es) 2019-05-13 2021-12-10 Regeneron Pharma Ensayos de union de ligandos competitivos mejorados.
US12473353B2 (en) 2019-05-15 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule, a pharmaceutical composition, and a method
US12264366B2 (en) 2019-05-17 2025-04-01 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
KR20220064953A (ko) 2019-06-21 2022-05-19 소리소 파마슈티컬스 인크. 폴리펩티드
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
TWI845745B (zh) * 2019-08-19 2024-06-21 洛克菲勒大學 具改良藥物動力學之經酸鹼度依賴性抗原結合活性工程化之抗人類免疫缺乏病毒抗體
CN110669778A (zh) * 2019-09-19 2020-01-10 上海药明生物技术有限公司 一种对抗体pH依赖结合活性的快速改造及筛选方法
CN120334439A (zh) 2019-09-24 2025-07-18 里珍纳龙药品有限公司 用于色谱介质的使用和再生的系统及方法
TWI832013B (zh) * 2019-09-30 2024-02-11 大陸商諾納生物（蘇州）有限公司 一種抗pd-l1抗原結合蛋白及其應用
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN119318636A (zh) 2019-11-25 2025-01-17 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
JP2023530997A (ja) * 2020-06-19 2023-07-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体
BR112023003273A2 (pt) 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
CN116710124A (zh) 2020-12-17 2023-09-05 瑞泽恩制药公司 包封蛋白质的微凝胶的制造
AU2022209730A1 (en) 2021-01-20 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
WO2022177870A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
JP2024519407A (ja) 2021-03-26 2024-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 混合プロトコルを作成するための方法およびシステム
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
WO2023044139A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
MX2024004107A (es) 2021-10-07 2024-04-19 Regeneron Pharma Sistemas y metodos para modelar y controlar el ph.
IL312372A (en) 2021-10-26 2024-06-01 Regeneron Pharma Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
CN119137473A (zh) 2022-03-18 2024-12-13 里珍纳龙药品有限公司 分析多肽变体的方法及系统
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
US20240255519A1 (en) 2023-02-01 2024-08-01 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024218743A1 (en) 2023-04-21 2024-10-24 Glycoera Ag Multi-functional molecules comprising glycans and uses thereof
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036633A (en) * 2008-12-15 2010-10-16 Regeneron Pharma High affinity human antibodies to PCSK9
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
EP1257572A2 (en) 2000-02-07 2002-11-20 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
WO2006007422A2 (en) 2004-06-16 2006-01-19 The Trustees Fo Columbia University In The City Of New York CaMKII/CALCIUM CHANNEL PHOSPHORYLATION-RELATED COMPOSITIONS AND METHODS
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
AU2007227251A1 (en) 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CN101636179B (zh) 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
EP2106261A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008057457A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
ES2618830T3 (es) 2006-12-08 2017-06-22 Lexicon Pharmaceuticals, Inc. Anticuerpos monoclonales contra ANGPTL3
EA200901376A1 (ru) 2007-04-13 2010-12-30 Новартис Аг Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
KR20100091191A (ko) 2007-10-26 2010-08-18 쉐링 코포레이션 항-ｐｃｓｋ9, 및 지질 및 콜레스테롤 질환의 치료 방법
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
US20120264146A1 (en) 2009-10-02 2012-10-18 The Regents Of The University Of California Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
CN105218674A (zh) 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
WO2012101253A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2013204581B2 (en) * 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
NZ712508A (en) 2012-03-16 2018-06-29 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036633A (en) * 2008-12-15 2010-10-16 Regeneron Pharma High affinity human antibodies to PCSK9
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding

Also Published As

Publication number Publication date
CA2881679A1 (en) 2014-02-20
US9540449B2 (en) 2017-01-10
UY34975A (es) 2014-03-31
TW201420605A (zh) 2014-06-01
MX363213B (es) 2019-03-15
WO2014028354A1 (en) 2014-02-20
CN104540852B (zh) 2018-10-02
EP2882778B1 (en) 2018-04-11
NZ704771A (en) 2018-02-23
KR20150041662A (ko) 2015-04-16
AR092098A1 (es) 2015-03-25
CA2881679C (en) 2021-01-26
AU2013302925A1 (en) 2015-02-26
MX2015001907A (es) 2015-06-05
US20140044730A1 (en) 2014-02-13
CN104540852A (zh) 2015-04-22
EA028244B1 (ru) 2017-10-31
EA201590370A1 (ru) 2015-05-29
JP2015526440A (ja) 2015-09-10
HK1211603A1 (en) 2016-05-27
JP6309521B2 (ja) 2018-04-11
EP2882778A1 (en) 2015-06-17
IL236785B (en) 2018-10-31
AU2013302925B2 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
TWI596115B (zh) 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
TWI465249B (zh) 針對ｐｃｓｋ９之高親和性人類抗體
JP6055055B2 (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
EP2459592B1 (en) High affinity human antibodies to human angiopoietin-2
JP6100697B2 (ja) グルカゴン受容体に対するヒト抗体
JP6000855B2 (ja) ヒトアンギオポエチン様タンパク質４に対するヒト抗体
JP7034068B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP2017533695A (ja) 抗グルカゴン抗体およびその使用
TW201313738A (zh) 人類類血管生成素蛋白３之人類抗體
US20140112930A1 (en) Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
HK1211603B (en) Anti-pcsk9 antibodies with ph-dependent binding characteristics
HK1166806B (en) High affinity human antibodies to human angiopoietin-2

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees